E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced Melanoma

Documenti analoghi

• Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
  di: Tarhini, Ahmad, et al.
  Pubblicazione: (2018)
• Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
  di: Sharma, Padmanee, et al.
  Pubblicazione: (2019)
• Sargramostim plus Ipilimumab vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial
  di: Hodi, F. Stephen, et al.
  Pubblicazione: (2014)
• Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
  di: Grimaldi, Antonio M, et al.
  Pubblicazione: (2014)
• Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
  di: Tarhini, Ahmad A., et al.
  Pubblicazione: (2020)